Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: A meta-Analysis of randomized controlled trials

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Ye, Xueshi ^a   Huang, Jinwen ^a   Pan, Qin ^a   Li, Wanli ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LENALIDOMIDE; THALIDOMIDE; IMMUNOLOGIC FACTOR;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG EFFECT; HAZARD RATIO; HUMAN; MAINTENANCE THERAPY; META ANALYSIS; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; AUTOTRANSPLANTATION; DISEASE FREE SURVIVAL; GENETIC HETEROGENEITY; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; STEM CELL TRANSPLANTATION;

DISEASE-FREE SURVIVAL; GENETIC HETEROGENEITY; HUMANS; IMMUNOLOGIC FACTORS; MAINTENANCE CHEMOTHERAPY; MIDDLE AGED; MULTIPLE MYELOMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS;

EID: 84903396998     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072635     Document Type: Article

References (27)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA et al. (2008) WHO classification of tumours of haematopoietic and lymphoid tissues, fourth edition. Lyon, France: IARC Press. pp. 202-207
2. Moreau P, Avet-Loiseau H, Harousseau JL, Attal M (2011) Current trends in autologous stem-cell transplantation for myeloma in the era of novel agents. J Clin Oncol 29: 1898-1906. doi:10.1200/JCO. 2010.32.5878. PubMed: 21482979
3. Fritz E, Ludwig H (2000) Interferon-Alpha treatment in multiple myeloma meta-Analysis of 30 randomized trials among 3948 patients. Ann Oncol 11: 1427-1436. doi:10.1023/A:1026548226770. PubMed: 11142483
4. Myeloma Trialists'. Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113: 1020-1034
5. Berenson JR, Crowley JJ, Grogan TM, Zangmeister J, Briggs AD et al. (2002) Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients. Blood 99: 3163-3168. doi: 10.1182/blood.V99.9.3163. PubMed: 11964279
6. Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP et al. (2007) A randomized comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY7. Br J Haematol 136: 203-211. doi:10.1111/j. 1365-2141.2006.06405.x. PubMed: 17233817
7. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P et al. (2012) Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1782-1791. doi:10.1056/ NEJMoa1114138. PubMed: 22571202
8. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H et al. (2012) Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366: 1770-1781. doi:10.1056/ NEJMoa1114083. PubMed: 22571201
9. Schulz KF, Altman DG, Moher D,CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 152: 726-732 doi: 10.7326/0003-4819-152-11-201006010-00232. PubMed: 20335313
10. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR (2007) Practical methods for incorporating summary time-To-event data into meta-Analysis. Trials 8: 16. doi:10.1186/1745-6215-8-16. PubMed: 17555582
11. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-Analyses. BMJ 327: 557-560. doi:10.1136/bmj. 327.7414.557. PubMed: 12958120
12. Barlogie B, Attal M, Crowley J, van Rhee F, Szymonifka J et al. (2010) Long-Term follow-up of autotransplantation trials for multiple myeloma: update of protocols conducted by the Intergroupe Francophone du Myelome, Southwest Oncology Group, and University of Arkansas for Medical Sciences. J Clin Oncol 28: 1209-1214. doi:10.1200/JCO. 2009.25.6081. PubMed: 20085933
13. Barlogie B, Pineda-Roman M, van Rhee F, Haessler J, Anaissie E et al. (2008) Thalidomide arm of total therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112: 3115-3121. doi:10.1182/ blood-2008-03-145235. PubMed: 18492953
14. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E et al. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 354: 1021-1030. doi:10.1056/NEJMoa053583. PubMed: 16525139
15. Stewart AK, Chen CI, Howson-Jan K, White D, Roy J et al. (2004) Results of a multicenter randomized phase II trial of thalidomide and prednisone maintenance therapy for multiple myeloma after autologous stem cell transplant. Clin Cancer Res 10: 8170-8176. doi: 10.1158/1078-0432.CCR-04-1106. PubMed: 15623591
16. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A et al. (2008) Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 111: 1805-1810. doi:10.1182/ blood-2007-07-101212. PubMed: 17875806
17. Lokhorst HM, van der Holt B, Zweegman S, Vellenga E, Croockewit S et al. (2010) A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma. Blood 115: 1113-1120. doi:10.1182/blood-2009-05-222539. PubMed: 19880501
18. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C et al. (2006) Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108: 3289-3294. doi:10.1182/ blood-2006-05-022962. PubMed: 16873668
19. Spencer A, Prince HM, Roberts AW, Prosser IW, Bradstock KF et al. (2009) Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27: 1788-1793. doi:10.1200/JCO.2008.18.8573. PubMed: 19273705
20. Stewart AK, Trudel S, Bahlis NJ, White DJ, Sabry W et al. (2010) A randomized phase III trial of thalidomide and prednisone as maintenance therapy following autologous stem cell transplantation (ASCT) in patients with multiple myeloma (MM): the NCIC CTG MY.10 trial. Blood (ASH Annual Meeting Abstracts). p. 116:39
21. Maiolino A, Hungria VT, Garnica M, Oliveira-Duarte G, Oliveira LC et al. (2012) Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Am J Hematol 87: 948-952. doi:10.1002/ajh.23274. PubMed: 22730113
22. Morgan GJ, Gregory WM, Davies FE, Bell SE, Szubert AJ et al. (2012) The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-Analysis. Blood 119: 7-15. doi: 10.1182/blood-2011-06-357038. PubMed: 22021371
23. Hicks LK, Haynes AE, Reece DE, Walker IR, Herst JA et al. (2008) A meta-Analysis and systematic review of thalidomide for patients with previously untreated multiple myeloma. Cancer Treat Rev 34: 442-452. doi:10.1016/j.ctrv.2008.02.003. PubMed: 18381234
24. Ludwig H, Hajek R, Tóthová E, Drach J, Adam Z et al. (2007) Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 113: 3435-3442. PubMed: 18955563
25. Facon T, Mary JY, Hulin C, Benboubker L, Attal M et al. (2007) Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370: 1209-1218. doi:10.1016/ S0140-6736(07)61537-2. PubMed: 17920916
26. Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE et al. (2000) Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 96: 2943-2950. PubMed: 11049970
27. Kagoya Y, Nannya Y, Kurokawa M (2012) Thalidomide maintenance therapy for patients with multiple myeloma: meta-Analysis. Leuk Res 36: 1016-1021. doi:10.1016/j.leukres.2012.04.001. PubMed: 22579366